276 related articles for article (PubMed ID: 32206746)
1. Promising therapeutic drug delivery systems for glaucoma: a comprehensive review.
Singh RB; Ichhpujani P; Thakur S; Jindal S
Ther Adv Ophthalmol; 2020; 12():2515841420905740. PubMed ID: 32206746
[TBL] [Abstract][Full Text] [Related]
2. Ocular drug delivery.
Gaudana R; Ananthula HK; Parenky A; Mitra AK
AAPS J; 2010 Sep; 12(3):348-60. PubMed ID: 20437123
[TBL] [Abstract][Full Text] [Related]
3. Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System.
Akhter MH; Ahmad I; Alshahrani MY; Al-Harbi AI; Khalilullah H; Afzal O; Altamimi ASA; Najib Ullah SNM; Ojha A; Karim S
Gels; 2022 Jan; 8(2):. PubMed ID: 35200463
[TBL] [Abstract][Full Text] [Related]
4. Nanocarriers for ocular drug delivery: current status and translational opportunity.
Gorantla S; Rapalli VK; Waghule T; Singh PP; Dubey SK; Saha RN; Singhvi G
RSC Adv; 2020 Jul; 10(46):27835-27855. PubMed ID: 35516960
[TBL] [Abstract][Full Text] [Related]
5. Sustained release ocular drug delivery systems for glaucoma therapy.
Al-Qaysi ZK; Beadham IG; Schwikkard SL; Bear JC; Al-Kinani AA; Alany RG
Expert Opin Drug Deliv; 2023; 20(7):905-919. PubMed ID: 37249548
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles in the ocular drug delivery.
Zhou HY; Hao JL; Wang S; Zheng Y; Zhang WS
Int J Ophthalmol; 2013; 6(3):390-6. PubMed ID: 23826539
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic contact lenses for the treatment of corneal and ocular surface diseases: Advances in extended and targeted drug delivery.
Abdi B; Mofidfar M; Hassanpour F; Kirbas Cilingir E; Kalajahi SK; Milani PH; Ghanbarzadeh M; Fadel D; Barnett M; Ta CN; Leblanc RM; Chauhan A; Abbasi F
Int J Pharm; 2023 May; 638():122740. PubMed ID: 36804524
[TBL] [Abstract][Full Text] [Related]
9. Review of the latest solutions in the use of contact lenses as controlled release systems for ophthalmic drugs.
Stiler-Wyszyńska S; Golba S; Jurek-Suliga J; Kuczkowski S
Polim Med; 2023; 53(1):47-58. PubMed ID: 36637332
[TBL] [Abstract][Full Text] [Related]
10. Ocular drug delivery systems: An overview.
Patel A; Cholkar K; Agrahari V; Mitra AK
World J Pharmacol; 2013; 2(2):47-64. PubMed ID: 25590022
[TBL] [Abstract][Full Text] [Related]
11. Topical ocular drug delivery systems: Innovations for an unmet need.
Yang Y; Lockwood A
Exp Eye Res; 2022 May; 218():109006. PubMed ID: 35248559
[TBL] [Abstract][Full Text] [Related]
12. Ocular Drug Delivery.
Yavuz B; Kompella UB
Handb Exp Pharmacol; 2017; 242():57-93. PubMed ID: 27783270
[TBL] [Abstract][Full Text] [Related]
13. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
Babizhayev MA; Kasus-Jacobi A
Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
[TBL] [Abstract][Full Text] [Related]
14. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies.
Mofidfar M; Abdi B; Ahadian S; Mostafavi E; Desai TA; Abbasi F; Sun Y; Manche EE; Ta CN; Flowers CW
Int J Pharm; 2021 Sep; 607():120924. PubMed ID: 34324989
[TBL] [Abstract][Full Text] [Related]
15. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
Nagstrup AH
Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases.
Onugwu AL; Nwagwu CS; Onugwu OS; Echezona AC; Agbo CP; Ihim SA; Emeh P; Nnamani PO; Attama AA; Khutoryanskiy VV
J Control Release; 2023 Feb; 354():465-488. PubMed ID: 36642250
[TBL] [Abstract][Full Text] [Related]
17. Topical sustained drug delivery to the retina with a drug-eluting contact lens.
Ross AE; Bengani LC; Tulsan R; Maidana DE; Salvador-Culla B; Kobashi H; Kolovou PE; Zhai H; Taghizadeh K; Kuang L; Mehta M; Vavvas DG; Kohane DS; Ciolino JB
Biomaterials; 2019 Oct; 217():119285. PubMed ID: 31299627
[TBL] [Abstract][Full Text] [Related]
18. Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy.
Luo LJ; Nguyen DD; Lai JY
Biomaterials; 2020 Jun; 243():119961. PubMed ID: 32171102
[TBL] [Abstract][Full Text] [Related]
19. Ocular Drug Delivery: Present Innovations and Future Challenges.
Gote V; Sikder S; Sicotte J; Pal D
J Pharmacol Exp Ther; 2019 Sep; 370(3):602-624. PubMed ID: 31072813
[TBL] [Abstract][Full Text] [Related]
20. Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review.
Dubald M; Bourgeois S; Andrieu V; Fessi H
Pharmaceutics; 2018 Jan; 10(1):. PubMed ID: 29342879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
